On July 15, 2025, bioAffinity Technologies, Inc. announced that it received patent allowance from the China National Intellectual Property Administration for a method to predict lung cancer using flow cytometry. This patent covers specific antibodies and porphyrin TCPP to detect lung cancer cells in sputum.